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This study was designed primarily to assess the safety and tolerability of fluticasone propionate (FP) 1 mg 
day - ’ by comparison with beclomethasone dipropionate (BDP) 2 mg day ~ ’ over a 12-month study period. 
Lung function data were also recorded and used to determine whether the potency ratio between the two 
inhaled corticosteroids observed in previous studies was maintained in the long-term. Two hundred and 
thirteen patients with an established clinical history of severe chronic asthma and who were currently receiving 
between 1000,ug and 2000,ug day- r of inhaled steroids were randomized to treatment in a ratio of 3:l for 
FP:BDP (159 patients FP; 54 patients BDP), both via metered dose inhalers. Both treatments were well 
tolerated with a similar adverse event profile. No unexpected adverse events were recorded. Most adverse 
events were related to the patients’ asthma, an intercurrent infection or underlying atopy. The incidence of 
pharmacologically predictable adverse events was equally low in both treatment groups as was the incidence 
of events suggestive of systemic steroid effect. Mean serum cortisol levels remained within the normal range 
at all visits for both treatments. At 12 months, however, the mean cortisol levels for the FP group had risen 
4% above the baseline value but had dropped 15% below for the BDP group, giving a ratio of FP:BDP of 1.22; 
P=O.Ol; 95% confidence limits (CL) 1.05-1.43. Fluticasone propionate 1 mg day-’ was at least as effective as 
BDP 2 mg day - ’ in improving lung function (PEF, FEV, and FVC) over this period. Moreover, the 
difference in FEV, values at 6 months was significantly greater for the FP group than for the BDP group 
(P=O.O4; difference=0.12 1; 95% CL=O.Ol, 0.24 1). The difference between treatments in the amount of FEV, 
reversibility was also significantly greater for FP at 12 months (difference in treatments= - 3%; 95% 
CL= - 7-O%; PzO.044). This study supports previous studies and suggests that FP is likely to be of benefit 
in the long-term treatment of chronic severe asthma. 
Introduction 
Asthma management guidelines now stress the 
importance of prompt treatment with inhaled corti- 
costeroids, even in cases of mild asthma (1,2). These 
guidelines recommend that the dose of corticosteroid 
should be titrated against the severity of disease, 
gradually reducing treatment in patients whose 
asthma has been stable for 3-6 months (3). Whilst the 
therapeutic benefits of corticosteroids are generally 
accepted, their safety, particularly when used long- 
term or in progressively greater doses, remains a 
cause for concern. 
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Inhaled steroids are associated with both local and 
systemic side-effects. Of these, local side-effects are 
typically oropharyngeal candidiasis, sore throat and 
cough (4). Their incidence appears to be related to 
dose, frequency and type of inhaler used, and may be 
reduced with the use of spacer devices (5). Overall, 
local side-effects of inhaled steroid treatment do not 
appear to represent a hazard to the patient. Systemic 
side-effects are potentially more serious. These may 
include suppression of the hypothalamic-pituitary- 
adrenal (HPA) axis, osteoporosis, skin thinning, 
weight gain, hypertension and reduced glucose 
tolerance (4-6). Whilst it is generally agreed that 
HPA-axis function is unlikely to be affected by doses 
of inhaled corticosteroids up to 15OOpg day - ’ 
(4,5,7), individual susceptibility to adrenal suppres- 
sion, and other unwanted systemic effects, varies 
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widely. Therefore, it is recognized that patients would 
benefit from the introduction of inhaled steroids 
which combine a high level of topical potency with 
minimum potential for systemic activity (58). 
Preclinical and clinical studies indicate that fluti- 
casone propionate (FP), a new topically active, tri- 
fluorinated glucocorticosteroid, may possess a better 
efficacy: risk ratio than other commonly prescribed 
inhaled corticosteroids. Fluticasone propionate has 
been shown to be less systemically available than 
other inhaled steroids by the oral route (9) and to be 
at least as effective as beclomethasone dipropionate 
(BDP) at half the microgram dosage (10-14). Studies 
comparing FP with budesonide in both metered-dose 
and dry powder inhalers, at low and high doses, 
suggest that the 2: 1 potency ratio also exists between 
these corticosteroids (15-18). In other studies which 
have compared equivalent doses, FP has been shown 
to have significantly better clinical efficacy than BDP 
and is as well tolerated (19,20) with no increased 
effect on basal or stimulated plasma cortisols (19). 
There are, however, only two published controlled 
studies” which have evaluated the efficacy of FP for a 
period of more than 6 or 12 weeks (14,19). In a 
previous study in patients with severe chronic 
asthma, FP 1 mg day - * was shown to have the 
efficacy of BDP 2 mg day- ’ over a 6-week treatment 
period (12). This present study was designed primar- 
ily to assess the safety and tolerability of FP 1 mg 
day ~ ’ by comparison with BDP 2 mg day - ’ over a 
1-yr study period. Lung function data were also 
recorded and used to determine whether the potency 
ratio between the two inhaled corticosteroids was 
maintained in the long term. 
Patients and Methods 
PATIENTS 
Patients with an established clinical history of 
severe chronic asthma, requiring and responding to 
&agonist therapy and treatment with high doses 
of inhaled corticosteroids, were recruited on an out- 
patient basis at 20 centres in seven countries in 
Europe. All the patients, aged between 18 and 77 
years, were receiving between 1000,~g and 2000,~g 
day ~ ’ of BDP or budesonide, and had no change to 
their regular asthma medication for at least 1 month. 
Patients entered a 2-week run-in period during 
which time they recorded the following details on 
daily record cards: the best of three assessments of 
peak expiratory flow (PEF), recorded once in the 
morning and once in the evening; asthma symptoms 
experienced by day and by night; and use of rescue 
medication. Asthma symptoms were assessed during 
the day from a scale which ranged from O=no 
asthma, to 3=unable to carry out usual activities, 
and during the night from a scale which ranged from 
O=slept well, no asthma, to 3 =awake most of the 
night. 
As the study was designed primarily to provide 
safety data over 1 yr, patients were recruited from 
those who were already stable on 1500&2OOOpg 
day- ’ inhaled corticosteroid or those who were 
mildly symptomatic on lOOO-15OOpg day- ’ inhaled 
corticosteroid. 
During the run-in period, patients receiving more 
than 1500,~g day-’ of an inhaled steroid were 
required to demonstrate that their asthma was stable. 
Stability was assessed from the results of lung func- 
tion tests, daily PEF data and a clinical examination. 
Patients receiving less than 1500 pug day - r of an 
inhaled steroid had either: (1) to exhibit asthma 
symptoms (with a score of at least 1) on no less than 
4 of the last 14 days of the run-in period; or (2) to 
demonstrate at least 15% reversibility in forced 
expiratory volume in 1 s (FEV, ) 15 min after inhal- 
ing 200,ug salbutamol from a metered dose inhaler or 
400 lug salbutamol from a Diskhaler. 
Patients were excluded from the study if any of the 
following applied: serious uncontrolled systemic dis- 
ease; recent admission to hospital with asthma; infec- 
tion of the upper or lower respiratory tract within 
the previous month; treatment with systemic cortico- 
steroids during the last month or on at least three 
occasions during the last 6 months; hypersensitivity 
to inhaled corticosteroids; treatment with other 
investigational drugs during the previous month; 
lactation, pregnancy or inadequate contraceptive 
precautions in women of child-bearing potential; 
evidence of alcohol abuse; inability to use a pressur- 
ized metered dose inhaler correctly; or inability or 
refusal to comply with any of the trial procedures. 
All the patients gave their written informed con- 
sent to participate in the study which had been 
approved by the local Ethics Committee. 
DESIGN 
This was a multi-centre, randomized, double-blind, 
parallel-group study of 12 months treatment. After a 
2-week run-in period, eligible patients were allocated 
randomly to receive either FP, two 250,~g actua- 
tions twice daily via a metered dose inhaler (MDI), 
with four actuations twice daily from a placebo 
MDI; or BDP four 250,~g actuations twice daily via 
an MD1 plus two actuations twice daily from a 
placebo MDI. Three patients were randomized 
to receive FP for every one patient randomized to 
receive BDP. 
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At the start of the 2-week run-in period, all pre- 
study bronchodilator therapy was replaced by 
inhaled salbutamol administered via MD1 to be used 
as required. All inhaled steroid medication was 
stopped at the end of the run-in period and replaced 
with the randomized study medication. Patients were 
allowed to use a Volumatic spacer device at the 
discretion of their physician. 
ASSESSMENTS 
There were eight clinic assessments during the 
study: at the beginning and end of the run-in period, 
after 1 and 2 months treatment, and at 3-monthly 
intervals thereafter until the end of the 1Zmonth 
treatment period. A follow-up visit was scheduled to 
take place 2 weeks after the cessation of study 
treatment. A full clinical history was obtained for 
each patient together with a physical examination 
which was repeated at the end of treatment. Vital 
signs and weight were measured at each clinic visit. 
Respiratory function tests at each clinic visit were: 
the best of three measurements of PEF, FEV, and 
forced vital capacity (FVC). Where possible, these 
were measured at the same time of day and when 
inhaled bronchodilator therapy had been withheld 
for at least 4 h. Reversibility of FEV, was measured 
15 min after inhaling salbutamol (2OOpg or 400 pug). 
ADVERSE EVENTS 
Irrespective of their supposed causal relationship 
to study treatment, details of all adverse events were 
recorded, as were any clinically significant shifts in 
the results of laboratory tests. Serious adverse events 
were defined as death, any life-threatening, disabling 
or incapacitating events, events requiring hospital- 
ization, congenital anomalies and cancer or drug 
overdose. 
ASTHMA EXACERBATIONS 
Asthma exacerbations recorded throughout the 
study were defined as an increase in asthma symp- 
toms which necessitated a change in therapy other 
than inhaled &-agonist. Patients with a worsening of 
asthma symptoms were instructed to measure their 
PEF using the mini-Wright peak flow meter pro- 
vided, then to record their symptoms and increase 
their use of inhaled bronchodilator. Patients were 
also advised to contact their investigator and report 
to the hospital clinic within 24 h of the onset 
of the symptoms. Where a short course of cortico- 
steroids was considered necessary, patients were pre- 
scribed 30-40 mg oral prednisolone daily. Patients 
whose symptoms improved after 48 h were gradually 
weaned off, whereas those who continued to require 
oral steroid therapy for longer than 3 weeks were 
withdrawn from this study. Patients were also with- 
drawn if they required systemic corticosteroids on 
more than four occasions during the course of the 
study. 
LABORATORY EVALUATIONS 
Blood samples for routine testing (haematology 
and biochemistry) were taken at the start of treat- 
ment, after 1, 2 and 3 months treatment, and there- 
after at 3-monthly intervals. When abnormal results 
had been obtained at the final clinic visit, blood 
sampling was repeated at the follow-up visit. Samples 
were taken from fasted patients between 0800 and 
1000h. A urine sample was also tested for the 
presence or absence of blood, protein or glucose 
using a dipstick. Serum cortisol concentrations were 
measured from blood samples taken at the same 
clinic visits. All samples were analysed by West 
Middlesex Laboratories, Clinical Biochemistry 
Department, Isleworth, Middlesex, U.K. The serum 
cortisol samples were analysed by radioimmuno- 
assay, using the coated-tube method with a between- 
batch coefficient of variation of 7%. 
Oropharyngeal swabs for Candida albicans were 
taken where indicated clinically by visual examin- 
ation at each clinic visit. 
STATISTICAL METHODS 
All statistical analyses were performed using SAS 
(release 6.07) programs and procedures. The analysis 
presented here is that of the total randomized popu- 
lation on an ‘intent to treat’ basis. In the analyses, 
two countries were identified with low patient num- 
bers (Austria (n=14) and Ireland (n=4)). All other 
countries recruited in excess of 24 patients. The 
results from Austria and Ireland were therefore 
grouped together. This action was unlikely to have 
had an effect on the study outcome since the number 
of patients involved was small. 
For each of the lung function, vital signs, weight 
and serum concentration parameters, analyses 
included adjusted means, treatment differences and 
95% confidence limits (95% CL) for the treatment 
differences. Lung function parameters (PEF, FEV,, 
FVC and reversibility in FEV,), vital signs and 
weight were analysed by analysis of covariance at 6 
and 12 months. The analysis accounted for variations 
due to country (with Austria and Ireland grouped), 
sex, age, use of spacer device and baseline. A log 
transformation was applied to the serum cortisol 
concentration data before it was subjected to the 
same statistical analyses as the clinic lung function 
data. Therefore, a treatment ratio rather than a 
difference was obtained for the serum cortisol data. 
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Table I Patient characteristics 
FP BDP 
500 pg bd 1000,ug bd Total 
No. of patients 
Males (%) 
Females (%) 
Caucasian (%) 
Age (years) 
Median 
Range 
Height mean (SD) cm 
Weight mean (SD) kg 
Smokers (%) 
Yes 
No 
Previous 
Duration of asthma (x) 
<lo yr 
210 yr 
Spacer used (%) 
159 54 213 
15 (47) 29 (54) 104 (49) 
84 (53) 25 (46) 109 (51) 
154 (97) 54 (100) 208 (98) 
51 54 52 
18-77 21-76 18-77 
168 (9) 171 (10) 169 (9) 
70 (13) 71 (14) 70 (13) 
29 (18) 12 (22) 41 (19) 
84 (53) 26 (48) 110 (52) 
46 (29) 16 (30) 62 (29) 
69 (43) 29 (54) 98 (45) 
90 (57) 25 (46) 115 (45) 
64 (40) 22 (41) 86 (40) 
FP, fluticasone propionate; BDP, beclomethasone dipropionate. 
Common adverse event rates were compared using 
Fisher’s exact test by doubling the one-sided test. The 
distribution of asthma exacerbations was analysed by 
Wilcoxon rank sum test. 
Results 
PATIENTS 
Patients were randomized to treatment in a ratio of 
3:l for FP:BDP. Of the total 213 patients randomized 
to treatment from 20 centres in seven different 
countries, 159 received FP and 54 received BDP. The 
two treatment groups were well matched for baseline 
characteristics, use of spacer device (Table l), con- 
comitant diseases and concurrent medications. Com- 
pliance to treatment was not assessed formally but 
inspection of returned medication revealed only a 
small percentage of ‘non-compliant’ patients (see 
below). 
During the study, 17% of patients in each treat- 
ment group withdrew from the trial for the following 
reasons: adverse events (13% and 9% in the FP and 
BDP groups, respectively), non-compliance (1% and 
2%, respectively), failure to return (3% in the FP 
group only) and treatment failure (1% and 6%, 
respectively). 
ADVERSE EVENTS 
The incidence of adverse events and drug-related 
adverse events was similar in both treatment groups. 
Seventy-two percent of the patients in each treatment 
group reported adverse events, the most common of 
which were related to asthma itself, an intercurrent 
infection or underlying atopy. The incidence of head- 
ache, more marked in patients taking BDP (four 
patients, 7%) than FP (one patient, cl%), was the 
only adverse event to show a significant difference 
between the two groups (P=O.O3). In both treatment 
groups, the incidence of pharmacologically predict- 
able adverse events such as oral candidiasis and 
hoarseness was low (Table 2). In the FP treatment 
group, there were two reports of fluid retention/ 
oedema and one each of menstrual disorders, weight 
gain and diabetes mellitus. The report of diabetes 
mellitus was considered to be unrelated to the study 
drug. In the BDP treatment group, there was one 
report of low cortisol and one of fluid retention/ 
oedema. 
Of the 25 patients who withdrew from the study 
due to an adverse event, 20 (13%) patients were 
receiving FP and five (9%) patients were receiving 
BDP. Some patients reported more than one adverse 
event as reason for withdrawal. A summation of 
events showed that the most common reason for 
withdrawal was asthma and related events (nine 
and four reports for FP and BDP, respectively). 
Other reasons for withdrawal included: ear, nose and 
throat disorders (four and one, respectively), cardio- 
vascular disorders (three reports FP), gastrointestinal 
disorders (three reports FP), neurological disorder 
(three reports FP), mouth and teeth disorders (two 
reports FP), abnormal cortisols (one report BDP), 
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Table 2 Summary of adverse events 
FP BDP 
500/q bd 1OOOfig bd 
No. of patients 
No. of patients with an 
adverse event (%) 
159 
114 (72) 39:472) 
Most common (>5% of patients) adverse events and those 
pharmacologically predictable 
Asthma and related events (%) 56 (35) 25 (46) 
Rhinitis (%) 16 (10) 2 (1) 
Bronchitis (%) 13 (8) 5 (9) 
Cough (%) 11 (7) 1 (2) 
Respiratory infection (%) 9 (6) 5 (9) 
Expectoration (%) 8 (5) 3 (6) 
Influenza (%) 8 (5) 7 (13) 
Sore throat (%) 7 (4) 4 (7) 
Urinary problems (%) 5 (3) 3 (6) 
Headache* (%) 1 (<l) 4 (7) 
Hoarseness? (%) 10 (6) 4 (7) 
Oral candidiasisf (%) 7 (4) 2 (4) 
FP, fluticasone propionate; BDP, beclomethasone 
dipropionate. 
*Statistically significant difference between treatments 
(P=O.O3). 
tPharmacologically predictable. 
hypersensitivity disorder (one report FP) and 
urogenital disorder (one report FP). 
Serious adverse events were reported by 11 patients 
(7%) in the FP group and three patients (6%) in the 
BDP group. Serious adverse events in the FP group 
were: Type I diabetes mellitus (one patient); myo- 
cardial infarction (two patients); hysterectomy (one 
patient), cataract operation (one patient) and salpin- 
gitis (one patient); and exacerbations of asthma or 
intercurrent infections (five patients). The three 
serious adverse events in the BDP group were: carci- 
noma of the prostate, syncope and exacerbation of 
asthma. Only one serious adverse event from the FP 
group (exacerbation of asthma) was considered by 
the investigator to be possibly related to study treat- 
ment. All other serious adverse event reports were 
considered to be unrelated to study treatment. 
LABORATORY EVALUATIONS 
No clinically significant abnormalities were 
detected in routine laboratory haematology, bio- 
chemistry or urinalysis parameters. 
CORTISOLS 
Figure 1 presents all the individual serum cortisol 
values as a scatter plot. The lower limit of the normal 
value of serum cortisol(l50 nmol I- ‘) is indicated on 
both axes. Patients in ‘Quadrant a’ are those who 
started the study with a lower than normal serum 
cortisol value which increased by the end of the study 
period; patients in ‘Quadrant b’ are those who started 
the study with a cortisol value above the lower limit 
which remained so at the end of the 12-month study 
period; patients in ‘Quadrant c’ are those who had a 
lower than normal value at baseline which remained 
low at the end of the study; and patients in ‘Quadrant 
d’ are those who started the study with a cortisol 
value above the lower limit which then fell below the 
lower limit at the end of the study. 
A comparison of the scatter plots shows that for 
both treatments, the majority of patients fell into 
‘Quadrant b’ and were above the lower limit of 
normal values after 12 months. Five patients (3%) in 
the FP treatment group and one patient (2%) in the 
BDP group had falls in serum cortisol values from 
above normal range to below the lower limit of the 
normal range (Quadrant d). Only one of these reports 
(from the BDP treatment group) was judged to be 
clinically significant. 
Whilst mean geometric serum cortisol levels in 
both treatment groups remained above the lower 
limit of the normal range throughout the study, the 
mean for patients taking FP was significantly higher 
at both the 6 and 12 month assessments (Table 3). 
After 12 months treatment, the adjusted geometric 
mean serum cortisol concentration in these patients 
had risen by 4% from baseline. By contrast, in 
patients taking BDP, the adjusted geometric mean 
fell by 15% from baseline. After 6 and 12 months of 
treatment, the respective adjusted geometric mean 
ratios of FP to BDP were: 1.23, 95% CL, 1.06-1.43; 
P=O.OOS and 1.22; 95% CL, 1.05-1.43; P=O.Ol. 
VITAL SIGNS 
No clinically relevant changes in weight, pulse rate, 
systolic or diastolic blood pressure were detected. 
EFFICACY 
The potency ratio between the two inhaled corti- 
costeroids was maintained over the 12-month study 
period. In terms of PEF, FEV, and FVC, FP 1 mg 
day - ’ was as effective as BDP 2 mg day- ’ over this 
period. Mean FEV, is shown in Fig. 2. The difference 
in FEV, between treatments at 6 months was signifi- 
cantly greater for the FP group than for the BDP 
group (P=O.O4; differencez0.12 1; 95% CL=O.Ol- 
0.24 1). Fluticasone propionate was also associated 
with a significantly greater improvement in FEV, 
reversibility at 12 months (difference in treatments in 
favour of FP= - 3%; 95% CL= - 7-O%; P=O.O44). 
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1000 10 
Baseline serum cortisol (nmol 1-l) 
Fig. I Scatter plots of individual serum cortisol means at baseline and after 12 months treatment with (a) fluticasone 
propionate 1 mg day ’ (n = 159) or (b) b ec omethasone 1 dipropionate 2 mg day- 1 (n=54). The lower limit of the normal 
range of serum cortisol values (150nmol I- ‘) is indicated on both axes. Patients in ‘Quadrant a’ were those who started the 
study with a lower than normal serum cortisol value which increased by the end of the study period; patients in ‘Quadrant 
b’ are those who started the study with a cortisol value above the lower limit which remained so at the end of the 12-month 
study period; patients in ‘Quadrant c’ are those who had a lower than normal visit at baseline which remained low at the 
end of the study; and patients in ‘Quadrant d’ are those who started the study with a cortisol value above the lower limit 
which then fell below the lower limit at the end of the study. 
Table 3 Geometric mean serum cortisol levels 
FP 
500 pug bd 
Adjusted? 
BDP mean ratio 95% 
1000,ag bd (FP/BDP) CL P value 
123 45 
349 299 
331 254 1.23 1.06-1.43 0.008 
0.95 0.85 
113 39 
365 312 
377 291 1.22 1.05-l ,43 0.010 
1.03 0.93 
6 months 
No. of patientst 
Baseline (nmol 1 - ‘) 
6 months (nmol 1 - ‘) 
Ratio* 
12 months 
No. of patients l- ’ 
Baseline (nmol 1~ ‘) 
12 months (nmol I- ‘) 
Ratio* 
FP, fluticasone propionate; BDP, beclomethasone dipropionate. 
*Ratio is calculated for each patient as the response at each clinic visit divided by the response 
at baseline. 
i-Mean ratios adjusted for baseline, country, age, sex and use of spacer device. 
ZPatients with data at start of treatment and at specified visit. 
There was no difference between treatments at any of no statistical difference between the two treatment 
the other time points. groups in the frequency of asthma exacerbations. The 
rate of occurrence of exacerbations remained fairly 
ASTHMA EXACERBATIONS constant over the 12-month period. 
Table 4 shows the frequency and rate of occurence 
of asthma exacerbations over the la-month treat- 
ment period. Sixty-one percent of patients on FP and Discussion 
52% of patients on BDP remained free of exacer- A substantial amount of data comparing FP with 
bations throughout the study period. There was BDP indicate that FP at half the dose is at least as 
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Months 
Fig. 2 Mean monthly FEV, values. *Significantly different 
between treatments (P=O.O4). 0, fluticasone propionate; 
n , beclomethasone dipropionate. 
effective in improving lung function and symptoms 
over the whole range of asthma severity and dosage 
(10-14). Furthermore, these studies demonstrate that 
the effect of FP on the HPA-axis is minimal, and 
either similar or significantly better than that of BDP. 
Very few published studies, however, have examined 
the effects of FP for longer than 12 weeks (14,19). 
The present study was, therefore, designed to assess 
the safety and tolerability of FP 1 mg day- r by 
comparison with BDP 2 mg day - r over 12 months 
and to determine whether the 2:l efficacy ratio for 
Table 4 Asthma exacerbations* 
BDP:FP was maintained at these doses over this 
period. 
As the objective was not to demonstrate efficacy, 
the subject population was drawn from patients with 
severe chronic asthma whose condition was either 
currently stable on 1500-2OOOpg day- ’ inhaled 
corticosteroid, or who suffered from only mild symp- 
toms on 1000-l 500 pug day - ’ inhaled corticosteroid. 
Since BDP has been studied extensively (4), the 
randomization schedule for this present study was 
structured in a 3:l ratio (FP:BDP) in order to 
increase the number of patients receiving FP. 
Lung function (FEV,, PEFR and FVC) improved 
from baseline values for both treatments, and the 2:l 
ratio for the doses of BDP:FP was maintained over 
the 12-month period. The rate of occurrence of 
asthma exacerbation confirmed that 1 mg day - ’ FP 
and 2 mg day r BDP provided good asthma control 
for up to 1 yr. 
Both treatments were well tolerated with similar 
adverse event profiles. No unexpected adverse events 
were recorded, and most of those recorded were 
related to the patients’ asthma, an intercurrent infec- 
tion or underlying atopy. The incidence of headache 
was significantly different between treatments with 
one report in the FP treatment group and four in 
the BDP treatment group. This finding is unlikely 
to hold any clinical significance since it has not 
been detected in previous studies (10-14) and the 
Frequency of asthma exacerbations 
Number of FP 5OOpg bd BDP IOOOpg bd 
exacerbations No. of patients No. of patients 
0 97 (61%) 28 (52%) 
1 35 (22%) 11 (20%) 
2 16 (10%) 10 (19%) 
3 7 (4%) 3 (6%) 
4 4 (3%) 1 (2%) 
5 0 (0%) 0 (0%) 
6 0 (0%) 1 (2%) 
Number of patients (%) with at least one exacerbation during each 3-monthly time interval 
Time interval (months) o-1 l-3 3-6 669 9912 
FP 5OOpug bd 11 (7%) 24 (15%) 16 (11%) 16 (11%) 17 (12%) 
BDP IOOOpg bd 7 (13%) 8 (15%) 13 (25%) 5 (10%) 6 (13%) 
FP, fluticasone propionate; BDP, beclomethasone dipropionate. 
*Asthma exacerbations were defined as asthma or related adverse events, 
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symptoms of headache are not uncommon in asth- 
matic patients. 
The incidence of pharmacologically predictable 
adverse events was equally low in both treatment 
groups, and too low to determine whether the use of 
a spacer device (40% of population) had affected the 
results. The incidence of events suggestive of systemic 
steroid effect (weight gain, menstrual disorders, fluid 
retention, diabetes mellitus) was low with a collective 
incidence of 3% of patients in the FP treatment group 
and less than 2% in the BDP group. The report of 
diabetes mellitus was considered to be unrelated to 
the study drug. 
In terms of serum cortisols, although all mean 
values were well within the normal range after 12 
months of treatment, they were 4% above mean 
baseline values in the FP group and 15% below 
baseline values in the BDP group. 
Several approaches have been used to assess HPA- 
axis function both in terms of basal function and 
adrenal reserve. These include measurements of 
morning serum cortisols levels, integrated serum cor- 
tisol levels, urinary free cortisol levels and serum 
cortisol response to tetracosactrin (4,21). There is, 
however, no general consensus as to the best method 
to use. Brown et al. (22) in one study found that low 
24-h urinary excretion of cortisol correlated well 
with low post-tetracosactrin cortisol concentrations, 
whereas plasma cortisol showed less sensitivity. How- 
ever, in a subsequent study, the same authors found 
that plasma cortisol was similar in sensitivity to 
post-tetracosactrin cortisol concentrations and uri- 
nary free cortisol (23). Other authors have suggested 
repeated serum cortisol determinations are more 
sensitive than single serum cortisol levels. (4) Clearly, 
however, serial serum cortisol measurements over 
24 h are impractical in asthmatic patients, and 
morning serum cortisol thus remains the most appro- 
priate measure of HPA-axis function in large-scale, 
multicentre clinical trials. 
It must be remembered, however, that the relation- 
ship between different measures of HPA-axis func- 
tion and the clinical relevance of changes in these 
measures is by no means clear (4). The HPA-axis is a 
very sensitive feedback system and small detectable 
changes in cortisol production are to be expected 
when exogenous corticosteroids are given. A decrease 
in basal cortisol production or an attenuation in the 
adrenal response to stimulation do not necessarily 
mean suppression of the HPA-axis function, merely 
that a corticosteroid is systemically available and 
pharmacologically active. Several studies investi- 
gating the effects of inhaled corticosteroids have 
identified so-called ‘suppression’ of HPA-axis func- 
tion in the absence of clinical adrenal insufficiency 
(24,25). 
The effect of treatments on bone metabolism was 
not assessed in the present study. Although there is 
some concern regarding the effects of inhaled corti- 
costeroids on bone metabolism (6) there is no defi- 
nite evidence from the literature that long-term 
treatment with inhaled corticosteroids is associated 
with an increased risk of osteoporosis or fracture in 
children or adults (4,21). Often the interpretation of 
the effects of inhaled cortisosteroids in patients with 
asthma is complicated by previous oral corticosteroid 
therapy (6). More long-term, prospective, controlled 
clinical studies are required to evaluate fully the 
effect of inhaled corticosteroids on growth and bone 
density which may not become apparent for several 
years. In a recent study, Ayres et al. found that serum 
cortisol monitoring rather than biochemical markers 
of bone metabolism appeared to be the most sensitive 
assay for measurement of systemic effect of high-dose 
inhaled steroids (18). 
Whilst treatment guidelines (1,2) are unanimous 
in recommending inhaled cortisosteroids, even for 
patients with mild asthma, many patients and physi- 
cians are wary of their long-term use and potential 
for systemic side-effects. The present study demon- 
strated that FP 1 mg day - ’ and BDP 2 mg day- i 
were well tolerated and unassociated with significant 
systemic effect over a 12-month period. In terms of 
lung function, FP 1 mg day ~ i was shown to be at 
least as effective as BDP 2 mg day- ’ throughout the 
12 months. The findings of this study support those 
of previous studies and suggest that FP is likely to be 
of benefit in the long-term treatment of asthma 
without affecting serum cortisols significantly. 
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